NADH Reductive Stress and Disease Severity in Leigh Syndrome: Insights from LC-MS/MS Quantification

Study Background and Research Question

Mitochondrial diseases such as Leigh syndrome are characterized by impaired cellular energy metabolism, most notably through dysfunction of the mitochondrial electron transport chain. Among the many metabolic markers investigated, the balance between reduced nicotinamide adenine dinucleotide (NADH) and its oxidized form (NAD⁺) has gained prominence as a critical indicator of mitochondrial redox state. Clinically, lactate has been widely adopted as a biomarker for mitochondrial dysfunction, but its specificity and quantitative relationship to disease severity remain limited. The reference study (Ishima et al., 2025) addresses this knowledge gap by probing whether direct measurement of the NADH/NAD⁺ ratio can offer a more precise and mechanistically informative biomarker for disease progression in Leigh syndrome, both in patient-derived fibroblasts and an established mouse model.

Key Innovation from the Reference Study

The central methodological advance in this work is the development and application of a streamlined liquid chromatography-tandem mass spectrometry (LC-MS/MS) protocol for the simultaneous, accurate quantification of NADH and NAD⁺. This approach overcomes key limitations of previous assays, which often relied on indirect measures—such as lactate levels—that could be confounded by non-mitochondrial factors. By enabling direct and sensitive quantification of both redox forms, the protocol allows for robust assessment of NADH reductive stress, a state characterized by an elevation in the NADH/NAD⁺ ratio due to electron transport chain impairment. The study demonstrates that this ratio, and specifically the absolute increase in NADH, correlates with disease severity in Leigh syndrome models, offering a more specific readout than traditional lactate assays (Ishima et al., 2025).

Methods and Experimental Design Insights

The investigators employed a two-pronged experimental strategy:

• Patient-Derived Fibroblast Analysis: Skin fibroblasts were obtained from pediatric patients diagnosed with Leigh syndrome and from healthy controls. The total NAD(H) pool, as well as individual levels of NADH and NAD⁺, were quantified using the newly developed LC-MS/MS method.
• Leigh Syndrome Mouse Model: To validate findings in an in vivo context, the team used a genetically engineered mouse model lacking the Ndufs4 subunit of mitochondrial complex I—a well-established genetic lesion underlying Leigh syndrome pathology. NADH and NAD⁺ levels were measured in tissues from knockout and wild-type animals.

In both systems, rigorous controls and statistical analysis were used to ensure specificity and reproducibility of the measurements. The LC-MS/MS protocol was optimized for sensitivity, rapid sample processing, and compatibility with routine clinical or laboratory workflows.

Core Findings and Why They Matter

• Elevation of NADH, Not NAD⁺: In patient fibroblasts, NAD⁺ levels were comparable to controls (p = 0.79), but NADH levels were significantly elevated (p = 0.04), resulting in a higher NADH/NAD⁺ ratio. Total NAD(H) content was unchanged, highlighting that reductive stress is driven by increased NADH rather than a depletion of NAD⁺ (Ishima et al., 2025).
• Validation in Mouse Model: The Ndufs4 knockout mice also exhibited a marked increase in NADH levels compared to wild-type (p = 0.002), confirming that elevated NADH is a consistent feature of mitochondrial complex I dysfunction.
• Diagnostic and Prognostic Implications: Unlike lactate, which may be confounded by other metabolic or systemic factors and does not always correlate with disease severity, NADH quantification provides a direct molecular readout of electron transport chain impairment. This positions the NADH/NAD⁺ ratio as a more robust biomarker for monitoring disease progression and potentially for evaluating therapeutic interventions.

Comparison with Existing Internal Articles

Several internal reviews and scenario-based articles reinforce the centrality of reduced nicotinamide adenine dinucleotide in both basic and applied biomedical research:

• The article "NAD+/NADH Balance Governs Hypoxic Adaptation in Filamentous Fungi" highlights the general principle that modulation of the NADH/NAD⁺ ratio orchestrates metabolic responses to hypoxic stress in eukaryotes, supporting the reference study's emphasis on redox state as a master regulator of cellular adaptation.
• "NADH in Photocatalytic Cancer Therapy and Advanced Redox..." discusses the mechanistic role of NADH in mitochondrial electron transport chain research and advanced therapeutic modalities, further illustrating the translational potential of NADH measurements in disease modeling and intervention.
• Application-focused internal resources such as "NADH (Reduced Nicotinamide Adenine Dinucleotide, CAS No...." and "Optimizing Cell Assays with NADH (Reduced-form) CAS No. 58-68-4" provide practical guidance for researchers implementing NADH in mitochondrial function assays, underscoring the need for validated reagents and protocols to ensure reproducibility—an issue directly addressed by the reference study’s optimized LC-MS/MS workflow.

Limitations and Transferability

While the study demonstrates clear utility of NADH quantification in fibroblasts and a genetically defined mouse model, several limitations remain:

• Sample Type Specificity: The findings are most robust in fibroblasts and brain tissue; extrapolation to other cell types or clinical fluids (e.g., blood, CSF) will require additional validation.
• Genetic Heterogeneity: Leigh syndrome is genetically diverse; thus, the correlation between NADH levels and disease severity may differ across mutations affecting other complexes or regulatory pathways.
• Clinical Implementation: Although LC-MS/MS is widely available in research settings, its adoption as a routine clinical biomarker assay will require standardization, cost analysis, and multi-center validation.

The protocol is most immediately transferable to research laboratories equipped with mass spectrometry, particularly those investigating mitochondrial disease mechanisms or testing metabolic interventions in cell and animal models.

Protocol Parameters

• Cell sample preparation: Use freshly cultured patient-derived fibroblasts or control lines; rapid quenching and extraction are essential to preserve redox state.
• LC-MS/MS analysis: Quantify NADH and NAD⁺ in parallel using a validated chromatographic separation and mass detection protocol; normalization to total protein or cell number is recommended (Ishima et al., 2025).
• Animal modeling: When using Ndufs4-KO mice to recapitulate Leigh syndrome, harvest tissues promptly and process under cold, low-oxygen conditions to prevent post-mortem redox changes.
• Interpretation: Compare NADH/NAD⁺ ratios to control samples and previous reference ranges to assess degree of reductive stress.

Research Support Resources

For laboratories seeking to reproduce or extend these workflows, high-purity reagents are critical. NADH (Reduced-form Nicotinamide Adenine Dinucleotide) CAS No. 58-68-4 (SKU C8749) is available from APExBIO and is validated for use in mitochondrial electron transport chain research, disease modeling, and metabolic assays. Researchers should refer to vendor protocols and recommended storage conditions to maintain reagent integrity for sensitive redox measurements. This product is intended for research use only and not for clinical diagnostics or therapeutic applications.